Background: Medications used in the treatment of dermatologic conditions have been associated with squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, and Merkel cell carcinoma (MCC). Objective: The objective of the study was to examine the relationship between systemic dermatologic medications and skin cancer in the FDA Adverse Event Reporting System (FAERS). Methods: Case-control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (RORs) for SCC, BCC, melanoma, and MCC. Results: The oral immunosuppressants were all associated with increased ROR of SCC, BCC, melanoma, and MCC. Azathioprine had the highest ROR for SCC (34.13, 95% CI 29.07–40.08), BCC (21.15, 95% CI 20.63–25.98), and MCC (44.76, 95% CI 31.52–63.55), while quinacrine and guselkumab had the highest ROR for melanoma (13.14, 95% CI 1.84–93.89 vs. 12.73, 95% CI 10.60–15.30, respectively). The TNF-α inhibitors were associated with an increased ROR for all skin cancers investigated. Conclusions: The oral immunosuppressants and many biologic medications were associated with an increased ROR of skin cancers including TNF-α inhibitors (etanercept, adalimumab, infliximab), IL-23 or IL-12/23 inhibitors (ustekinumab, risankizumab), and the CD-20 inhibitor rituximab but not dupilumab or IL-17 inhibitors.

Keywords:
TNF-α inhibitors, IL-12/23 inhibitor, IL-23 inhibitor, IL-17 inhibitor, Skin cancer
1.
Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177–86.
https://doi.org/10.1016/s0190-9622(99)70185-4
2.
Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012 Oct;87(10):991–1003.
https://doi.org/10.1016/j.mayocp.2012.04.018
3.
Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers. 2014 Jun 27;6(3):1328–50.
https://doi.org/10.3390/cancers6031328
4.
Harwood CA, Toland AE, Proby CM, Euvrard S, Hofbauer GFL, Tommasino M, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017 Nov;177(5):1217–24.
https://doi.org/10.1111/bjd.15956
5.
Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: a review of risk factors and models of care. Am J Clin Dermatol. 2018 Aug;19(4):585–97.
https://doi.org/10.1007/s40257-018-0355-8
6.
Wang JL, Yin WJ, Zhou LY, Zhou G, Liu K, Hu C, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769–78.
https://doi.org/10.1007/s10067-019-04865-y
7.
Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021 Jan 9;22(2):11.
https://doi.org/10.1007/s11864-020-00815-y
8.
US Food and Drug Administration. FDA Adverse Event Reporting System Public Dashboard. FDA; 2022.
9.
MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities: MedDRA v23.0. Medical Dictionary for Regulatory Activities; 2022.
10.
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019 Apr;74(2):225–32.
https://doi.org/10.1016/j.therap.2019.01.006
11.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001 Nov 1;125(1–2):279–84.
https://doi.org/10.1016/s0166-4328(01)00297-2
12.
Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern?Curr Infect Dis Rep. 2011 Dec;13(6):536–43.
https://doi.org/10.1007/s11908-011-0220-x
13.
LE Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol. 2012 Apr;39(4):712–5.
https://doi.org/10.3899/jrheum.110982
14.
Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int. 2021 Nov 22;21(1):614.
https://doi.org/10.1186/s12935-021-02325-9
15.
Cardwell L, Sullivan B, Baran E, Oussedik E, Feldman SR. TNF inhibitors for psoriasis and psoriatic arthritis. Curr Derm Rep. 2017;6(2):113–20.
https://doi.org/10.1007/s13671-017-0174-9
16.
Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.
https://doi.org/10.1080/19420862.2021.1964420
17.
O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005 Sep 16;309(5742):1871–4.
https://doi.org/10.1126/science.1114233
18.
Johnson NM, Prickett KA, Phillips MA. Systemic medications linked to an increased risk for skin malignancy. Cutis. 2019 Oct;104(4):E32–6.
19.
Gu YH, Du JX, Ma ML. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4335–9.
https://doi.org/10.7314/apjcp.2012.13.9.4335
20.
Murray SL, Daly FE, O’Kelly P, O’Leary E, Deady S, O’Neill JP, et al. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail. 2020 Nov;42(1):607–12.
https://doi.org/10.1080/0886022X.2020.1785499
21.
van Lumig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):752–60.
https://doi.org/10.1111/jdv.12675
22.
Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017 Nov;77(5):845–54.e5.
https://doi.org/10.1016/j.jaad.2017.07.013
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.